Display Settings:

Format

Send to:

Choose Destination
    Bioorg Med Chem Lett. 2008 Sep 1;18(17):4789-93. Epub 2008 Jul 27.

    An osteoclast-targeting agent for imaging and therapy of bone metastasis.

    Source

    Department of Radiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, TX 75390, USA.

    Abstract

    A hybrid compound (DO3A-BP) featuring a radiometal bifunctional chelator (1,4,7,10-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid, DOTA) and an osteoclast-targeting moiety (bisphosphonate) was designed and synthesized. The (111)In-labeled complex of DO3A-BP showed significantly elevated uptake in osteoclasts compared to the undifferentiated adherent bone marrow derived cells. Biodistribution studies revealed a favorable tissue distribution profile in normal mice with high bone uptake and long retention, and low or negligible accumulation in non-target organs.

    PMID:
    18692394
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2553272
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2
    Scheme 1
    Scheme 2
    Figure 1
    Figure 3

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk